Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Researchers should determine the optimal concentration of this reagent for their individual applications.
- BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- Pacific Blue™ is a trademark of Life Technologies Corporation.
Companion Products
The B-D44 monoclonal antibody specifically recognizes CD263 which is also known as, TNF-related apoptosis-inducing ligand receptor 3 (TRAIL Receptor 3/TRAIL-R3), Decoy receptor 1 (DCR1), Lymphocyte inhibitor of TRAIL (LIT), or TRID. CD263 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that belongs to the TNF Receptor Superfamily which includes other TRAIL (CD253/APO-2 Ligand) Receptors: CD261 (TRAIL-R1), CD262 (TRAIL-R2), and CD264 (TRAIL-R4). Unlike CD261 or CD262 that contain an intracellular signaling death domain, CD263 (and CD264) lacks a cytoplasmic death domain and is unable to transduce apoptotic signals upon binding TRAIL. CD263 thus serves as a decoy receptor for TRAIL. It functions as a negative regulator of apoptotic signaling by competing with CD261 and CD262 for the binding of TRAIL. Overexpression of CD263 can reportedly attenuate TRAIL-induced apoptosis.
Development References (6)
-
Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol. 2007; 179(8):5441-5453. (Biology). View Reference
-
Bisgin A, Terzioglu E, Aydin C, et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010; 11(192):200. (Biology). View Reference
-
Ch'en PF, Xu XG, Liu XS, et al. Characterisation of monoclonal antibodies to the TNF and TNF receptor families. Cell Immunol. 2005; 236(1-2):78-85. (Biology). View Reference
-
Gottwald L, Piekarski J, Kubiak R, et al. Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study. Arch Gynecol Obstet. 2013; 4(889):899. (Biology). View Reference
-
Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biochem. 2006; 26(19):7046-7055. (Biology). View Reference
-
Vermot-Desroches C, Sergent E, Bonnin B, Wijdenes J. Characterization of monoclonal antibodies directed against trail or trail receptors. Cell Immunol. 2005; 236(1-2):86-91. (Clone-specific: Flow cytometry). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
